BACKGROUND: Research suggests an association between abnormal exocytosis and schizophrenia. We previously demonstrated increased synaptosomal associated protein, 25 kDa (SNAP-25), a member of the exocytotic mechanism, in the cerebrospinal fluid (CSF) of schizophrenia subjects. In this study, we explored SNAP-25 level and clinical variables in a new group of subjects. METHODS: Twenty-five haloperidol-treated subjects with chronic schizophrenia and twenty-five healthy control subjects participated in the study. Subjects received haloperidol treatment for at least 3 months and then had a lumbar puncture (n = 19). Medication was replaced by placebo, and the lumbar puncture was repeated (n = 25) after 6 weeks or sooner if limited psychotic symptoms occurred. We measured the level of SNAP-25 in the CSF and symptoms with the Brief Psychiatric Rating Scale (BPRS). RESULTS: In both haloperidol (p =.001) and placebo (p =.001) treatment conditions, SNAP-25 was elevated. There was no significant difference in SNAP-25 level between conditions. We identified significant positive correlations among SNAP-25 and the BPRS total score and psychosis and thinking disturbance subscales in subjects on haloperidol. CONCLUSIONS: These observations confirm our previous report of elevated CSF SNAP-25 and suggest that synaptic pathology may be linked with the pathophysiology of schizophrenia.
RCT Entities:
BACKGROUND: Research suggests an association between abnormal exocytosis and schizophrenia. We previously demonstrated increased synaptosomal associated protein, 25 kDa (SNAP-25), a member of the exocytotic mechanism, in the cerebrospinal fluid (CSF) of schizophrenia subjects. In this study, we explored SNAP-25 level and clinical variables in a new group of subjects. METHODS: Twenty-five haloperidol-treated subjects with chronic schizophrenia and twenty-five healthy control subjects participated in the study. Subjects received haloperidol treatment for at least 3 months and then had a lumbar puncture (n = 19). Medication was replaced by placebo, and the lumbar puncture was repeated (n = 25) after 6 weeks or sooner if limited psychotic symptoms occurred. We measured the level of SNAP-25 in the CSF and symptoms with the Brief Psychiatric Rating Scale (BPRS). RESULTS: In both haloperidol (p =.001) and placebo (p =.001) treatment conditions, SNAP-25 was elevated. There was no significant difference in SNAP-25 level between conditions. We identified significant positive correlations among SNAP-25 and the BPRS total score and psychosis and thinking disturbance subscales in subjects on haloperidol. CONCLUSIONS: These observations confirm our previous report of elevated CSF SNAP-25 and suggest that synaptic pathology may be linked with the pathophysiology of schizophrenia.
Authors: Vilte E Barakauskas; Clare L Beasley; Alasdair M Barr; Athena R Ypsilanti; Hong-Ying Li; Allen E Thornton; Hubert Wong; Gorazd Rosokilja; J John Mann; Branislav Mancevski; Zlatko Jakovski; Natasha Davceva; Boro Ilievski; Andrew J Dwork; Peter Falkai; William G Honer Journal: Neuropsychopharmacology Date: 2010-01-13 Impact factor: 7.853
Authors: A H Fanous; Z Zhao; E J C G van den Oord; B S Maher; D L Thiselton; S E Bergen; B Wormley; T Bigdeli; R L Amdur; F A O'Neill; D Walsh; K S Kendler; B P Riley Journal: Am J Med Genet B Neuropsychiatr Genet Date: 2010-03-05 Impact factor: 3.568
Authors: Peter L Oliver; Melanie V Sobczyk; Elizabeth S Maywood; Benjamin Edwards; Sheena Lee; Achilleas Livieratos; Henrik Oster; Rachel Butler; Sofia I H Godinho; Katharina Wulff; Stuart N Peirson; Simon P Fisher; Johanna E Chesham; Janice W Smith; Michael H Hastings; Kay E Davies; Russell G Foster Journal: Curr Biol Date: 2012-01-19 Impact factor: 10.834
Authors: Heidi O Nousiainen; Ileana B Quintero; Timo T Myöhänen; Vootele Voikar; Jelena Mijatovic; Mikael Segerstråle; Annakaisa M Herrala; Natalia Kulesskaya; Anitta E Pulkka; Tanja Kivinummi; Usama Abo-Ramadan; Tomi Taira; T Petteri Piepponen; Heikki Rauvala; Pirkko Vihko Journal: PLoS One Date: 2014-05-20 Impact factor: 3.240